Paper23945458
A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
Cusin C and 6 others. J Clin Psychiatry, 2013. Cited by 77 papers, by iCite.
Cite this record
ConductScience Library. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. Papers, record 23945458. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23945458
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antidepressive Agents | Major topic |
| Benzothiazoles | Major topic |
| Major Depressive Disorder | Major topic |
| Depressive Disorder, Treatment-Resistant | Major topic |
| Adult | |
| Aged | |
| Diagnostic and Statistical Manual of Mental Disorders | |
| Dopamine Agonists | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Drug Monitoring | |
| Drug Synergism | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Pramipexole | |
| Psychiatric Status Rating Scales | |
| Remission Induction | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| K23 MH067060 | NIMH NIH HHS | United States | K23MH067060 | PubMed and NIH |
| K23-MH67060 | NIMH NIH HHS | United States | K23MH067060 | PubMed and NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00231959 | Effectiveness of Pramipexole for Treatment-Resistant Depression | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 24308279 | Pramipexole augmentation in treatment-resistant major depressive disorder. | https://conductscience.org/library/papers/24308279 |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15820269 | Dopaminergic mechanism of antidepressant action in depressed patients. | J Affect Disord | 2005 | https://conductscience.org/library/papers/15820269 | PubMed |
| 2 | 11556901 | Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens. | Eur J Neurosci | 2001 | https://conductscience.org/library/papers/11556901 | PubMed |
| 3 | 14971628 | The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. | Psychol Med | 2004 | https://conductscience.org/library/papers/14971628 | PubMed |
| 4 | 10889548 | Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. | Mol Psychiatry | 2000 | https://conductscience.org/library/papers/10889548 | PubMed |
| 5 | 11458990 | The effect of repeated treatment with pramipexole on the central dopamine D3 system. | J Neural Transm (Vienna) | 2000 | https://conductscience.org/library/papers/11458990 | PubMed |
| 6 | 7664822 | Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. | Eur J Pharmacol | 1995 | https://conductscience.org/library/papers/7664822 | PubMed |
| 7 | 444788 | A new depression scale designed to be sensitive to change. | Br J Psychiatry | 1979 | https://conductscience.org/library/papers/444788 | PubMed |
| 8 | 16279288 | The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. | Clin Trials | 2004 | https://conductscience.org/library/papers/16279288 | PubMed |
| 9 | 3820220 | Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine. | J Med Chem | 1987 | https://conductscience.org/library/papers/3820220 | PubMed |
| 10 | 21154393 | Second-generation antipsychotics for major depressive disorder and dysthymia. | Cochrane Database Syst Rev | 2010 | https://conductscience.org/library/papers/21154393 | PubMed |
| 11 | 20708060 | Pramipexole for stage 2 treatment-resistant major depression: an open study. | Prog Neuropsychopharmacol Biol Psychiatry | 2010 | https://conductscience.org/library/papers/20708060 | PubMed |
| 12 | 12479663 | Pramipexole in treatment-resistant depression: a 16-week naturalistic study. | Bipolar Disord | 2002 | https://conductscience.org/library/papers/12479663 | PubMed |
| 13 | 22770672 | Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder. | J Psychiatr Res | 2012 | https://conductscience.org/library/papers/22770672 | PubMed |
| 14 | 10817524 | Synergistic effect of pramipexole and sertraline in the forced swimming test. | Pol J Pharmacol | 1999 | https://conductscience.org/library/papers/10817524 | PubMed |
| 15 | 10812530 | Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. | Depress Anxiety | 2000 | https://conductscience.org/library/papers/10812530 | PubMed |
| 16 | 9347387 | The mesolimbic dopamine system as a target for rapid antidepressant action. | Int Clin Psychopharmacol | 1997 | https://conductscience.org/library/papers/9347387 | PubMed |
| 17 | 15669893 | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. | J Clin Psychiatry | 2005 | https://conductscience.org/library/papers/15669893 | PubMed |
| 18 | 20175941 | Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. | Int J Neuropsychopharmacol | 2010 | https://conductscience.org/library/papers/20175941 | PubMed |
| 19 | 17335320 | A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. | J Clin Psychiatry | 2007 | https://conductscience.org/library/papers/17335320 | PubMed |
| 20 | 9137910 | The behavioural effects of pramipexole, a novel dopamine receptor agonist. | Eur J Pharmacol | 1997 | https://conductscience.org/library/papers/9137910 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42638752 | Pramipexole treatment and substance use disorder risk in unipolar and bipolar depression: a Swedish nationwide register study. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42638752 | PubMed |
| 42286321 | Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial. | Nat Med | 2026 | https://conductscience.org/library/papers/42286321 | PubMed |
| 41057811 | Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications. | BMC Psychiatry | 2025 | https://conductscience.org/library/papers/41057811 | PubMed |
| 40754997 | Are There Connections between the Neuroendocrine and Dopamine Systems in Bipolar Disorder? | Neuroendocrinology | 2025 | https://conductscience.org/library/papers/40754997 | PubMed |
| 38035737 | Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden. | BMJ Open | 2023 | https://conductscience.org/library/papers/38035737 | PubMed |
| 37982928 | Pramipexole for the Treatment of Depression: Efficacy and Mechanisms. | Curr Top Behav Neurosci | 2024 | https://conductscience.org/library/papers/37982928 | PubMed |
| 37109571 | Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis. | Life (Basel) | 2023 | https://conductscience.org/library/papers/37109571 | PubMed |
| 35795852 | Hydroalcoholic Leaf Extract of Isatis tinctoria L. via Antioxidative and Anti-Inflammatory Effects Reduces Stress-Induced Behavioral and Cellular Disorders in Mice. | Oxid Med Cell Longev | 2022 | https://conductscience.org/library/papers/35795852 | PubMed |
| 34986373 | Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. | J Affect Disord | 2022 | https://conductscience.org/library/papers/34986373 | PubMed |
| 34872405 | Habitual caffeine consumption moderates the antidepressant effect of dorsomedial intermittent theta-burst transcranial magnetic stimulation. | J Psychopharmacol | 2021 | https://conductscience.org/library/papers/34872405 | PubMed |
| 34810175 | PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression. | Evid Based Ment Health | 2022 | https://conductscience.org/library/papers/34810175 | PubMed |
| 34404915 | Influences of dopaminergic system dysfunction on late-life depression. | Mol Psychiatry | 2022 | https://conductscience.org/library/papers/34404915 | PubMed |
| 34285088 | Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. | Pharmacol Rev | 2021 | https://conductscience.org/library/papers/34285088 | PubMed |
| 33658867 | Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder. | J Exp Pharmacol | 2021 | https://conductscience.org/library/papers/33658867 | PubMed |
| 32440593 | Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression. | Chronic Stress (Thousand Oaks) | 2019 | https://conductscience.org/library/papers/32440593 | PubMed |
| 31496702 | Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study. | Neuropsychiatr Dis Treat | 2019 | https://conductscience.org/library/papers/31496702 | PubMed |
| 31376815 | Sleep therapeutics and neuropsychiatric illness. | Neuropsychopharmacology | 2020 | https://conductscience.org/library/papers/31376815 | PubMed |
| 30041971 | Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study. | Biol Psychiatry | 2018 | https://conductscience.org/library/papers/30041971 | PubMed |
| 29173175 | Imaging the Role of Inflammation in Mood and Anxiety-related Disorders. | Curr Neuropharmacol | 2018 | https://conductscience.org/library/papers/29173175 | PubMed |
| 29106542 | Dopamine System Dysregulation in Major Depressive Disorders. | Int J Neuropsychopharmacol | 2017 | https://conductscience.org/library/papers/29106542 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| DRD4 | 1815 | PubTator's text mining | https://conductscience.org/library/genes/1815 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PRAMIPEXOLE | CHEMBL301265 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL301265 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23945458
GET https://conductscience.org/api/papers/v1/23945458/references?page=2